Certara, Inc. (NASDAQ:CERT) Receives $12.82 Consensus Target Price from Brokerages

Certara, Inc. (NASDAQ:CERT) has received an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $12.8182.

CERT has been the subject of a number of recent research reports. BMO Capital Markets assumed coverage on shares of Certara in a research report on Thursday, November 13th. They set a “market perform” rating and a $9.00 price target for the company. Rothschild & Co Redburn set a $10.00 price objective on shares of Certara in a research note on Friday, November 21st. Morgan Stanley decreased their target price on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. Barclays lowered their price target on shares of Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Monday, December 15th. Finally, KeyCorp reduced their price objective on Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, January 8th.

Certara Stock Up 0.3%

Shares of CERT stock opened at $6.53 on Thursday. Certara has a fifty-two week low of $6.44 and a fifty-two week high of $15.38. The firm has a market capitalization of $1.04 billion, a PE ratio of 93.29 and a beta of 1.47. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.09 and a current ratio of 2.09. The stock’s 50-day simple moving average is $8.66 and its 200-day simple moving average is $10.07.

Institutional Investors Weigh In On Certara

Several hedge funds have recently bought and sold shares of the stock. Tejara Capital Ltd lifted its holdings in Certara by 94.9% during the third quarter. Tejara Capital Ltd now owns 273,052 shares of the company’s stock valued at $3,337,000 after purchasing an additional 132,927 shares in the last quarter. Sector Gamma AS purchased a new position in Certara in the 3rd quarter valued at about $2,818,000. Fort Washington Investment Advisors Inc. OH acquired a new stake in Certara in the 3rd quarter worth about $11,899,000. Intech Investment Management LLC acquired a new stake in Certara in the 2nd quarter worth about $329,000. Finally, Versor Investments LP increased its stake in Certara by 104.0% during the 2nd quarter. Versor Investments LP now owns 89,346 shares of the company’s stock worth $1,045,000 after buying an additional 45,546 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.